Major pharmacy group criticizes FTC decision on PBMs

Anthony Vecchione | | Health Exec | Policy & Regulations
Pharmacy

The trade group representing community pharmacists lambasted the FTC’s recent ruling regarding the contracting practices of pharmacy benefit managers (PBMs).

The FTC voted 2-2 on Thursday to not investigate PBMs' competitive impact on contractual provisions, reimbursement adjustments, and other practices affecting drug prices, including those practices that may disadvantage independent or specialty pharmacies.

“Two members of the FTC just let the worst actors in the market off the hook,” B. Douglas Hoey, CEO of the National Community Pharmacists Association (NCPA), said in a prepared statement.

 “After hearing hours of testimony by community pharmacists and patients, all of whom painted the same shocking picture about PBM abuse, and not a single witness there to defend the PBM industry, it is inexplicable that two members of the commission could vote against the study. Their decisions could not possibly have been based on what was heard today," Hoey went on to say.

Hoey added that while he is grateful to FTC Chairwoman Lina Khan for bringing the issue to a vote, he said that NCPA will demand that the topic be revisited as soon as possible.

Anthony Vecchione

Related Content

Public health contrarian RFK Jr. nominated to HHS secretary
Surgical devices recalled after 17 serious injuries—FDA warns of possible shortage
Cardiologist demand is on the rise—can hospitals keep up?
AdvaMed itemizes AI imperatives for ‘the entire healthcare ecosystem’
UnitedHealth defends $3.3B Amedisys acquisition
DOJ sues to block UnitedHealth’s $3.3B acquisition of home health giant

Around the web

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Design by Adaptive Theme
Trimed Popup
Trimed Popup